LT3077544T - Racionalia logika pagrįstas tikslinės vėžio terapijos modelis - Google Patents
Racionalia logika pagrįstas tikslinės vėžio terapijos modelisInfo
- Publication number
- LT3077544T LT3077544T LTEP14867137.3T LT14867137T LT3077544T LT 3077544 T LT3077544 T LT 3077544T LT 14867137 T LT14867137 T LT 14867137T LT 3077544 T LT3077544 T LT 3077544T
- Authority
- LT
- Lithuania
- Prior art keywords
- rationale
- cancer
- targeted therapy
- based design
- design
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911423P | 2013-12-03 | 2013-12-03 | |
| PCT/US2014/068373 WO2015084958A1 (en) | 2013-12-03 | 2014-12-03 | Rationale-based design of a targeted therapy for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3077544T true LT3077544T (lt) | 2019-07-10 |
Family
ID=53274072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14867137.3T LT3077544T (lt) | 2013-12-03 | 2014-12-03 | Racionalia logika pagrįstas tikslinės vėžio terapijos modelis |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9782418B2 (lt) |
| EP (1) | EP3077544B1 (lt) |
| CN (1) | CN106029905B (lt) |
| AU (1) | AU2014360503A1 (lt) |
| DK (1) | DK3077544T3 (lt) |
| ES (1) | ES2732445T3 (lt) |
| LT (1) | LT3077544T (lt) |
| PT (1) | PT3077544T (lt) |
| WO (1) | WO2015084958A1 (lt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014360503A1 (en) * | 2013-12-03 | 2016-06-30 | Celestra Life Science Llc | Rationale-based design of a targeted therapy for cancer |
| CN108220242A (zh) * | 2016-12-10 | 2018-06-29 | 中国科学院大连化学物理研究所 | Spop及突变体表达的c4-2稳定细胞系及构建方法 |
| CN107299133A (zh) * | 2017-06-09 | 2017-10-27 | 上海长海医院 | 一种前列腺癌的标志物spop及其在指导肿瘤治疗中的应用 |
| CN110396544B (zh) * | 2019-06-19 | 2021-12-24 | 山东大学齐鲁医院 | Cul7在胶质瘤诊断、治疗和预后中的应用 |
| US20220249545A1 (en) * | 2019-07-11 | 2022-08-11 | Emory University | Platinum-Based Chemotherapy, Mast Binding Agents, Glucocorticoid Receptor (GR) Binding Agents, and/or HSP90 Binding Agents for Uses in Treating Cancer |
| CN110970087B (zh) * | 2019-12-31 | 2021-08-03 | 华中科技大学 | 一种鉴定调控细胞自噬的功能激酶的方法 |
| CN111671760A (zh) * | 2020-06-10 | 2020-09-18 | 谭志荣 | 人参皂苷ck在制备抗结直肠癌药物中的应用 |
| KR20230093329A (ko) | 2020-10-28 | 2023-06-27 | 베이롤 칼리지 오브 메드신 | 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101489562B (zh) * | 2006-07-21 | 2012-04-18 | 赛福伦公司 | 用于治疗脊髓增生病的jak抑制剂 |
| US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| AR070479A1 (es) * | 2008-02-26 | 2010-04-07 | Takeda Pharmaceutical | Derivado heterociclico fusionado y su uso |
| DE102008031699A1 (de) * | 2008-07-04 | 2010-01-14 | Protagen Ag | Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung |
| WO2010021822A2 (en) * | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
| WO2011066344A1 (en) * | 2009-11-25 | 2011-06-03 | Dana-Farber Cancer Institute, Inc. | Crlf2 in precursor b-cell acute lymphoblastic leukemia |
| WO2012092339A2 (en) * | 2010-12-28 | 2012-07-05 | The Children's Hospital Of Philadelphia | The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
| AU2014360503A1 (en) | 2013-12-03 | 2016-06-30 | Celestra Life Science Llc | Rationale-based design of a targeted therapy for cancer |
-
2014
- 2014-12-03 AU AU2014360503A patent/AU2014360503A1/en not_active Abandoned
- 2014-12-03 CN CN201480074107.9A patent/CN106029905B/zh active Active
- 2014-12-03 WO PCT/US2014/068373 patent/WO2015084958A1/en active Application Filing
- 2014-12-03 PT PT14867137T patent/PT3077544T/pt unknown
- 2014-12-03 DK DK14867137.3T patent/DK3077544T3/da active
- 2014-12-03 ES ES14867137T patent/ES2732445T3/es active Active
- 2014-12-03 LT LTEP14867137.3T patent/LT3077544T/lt unknown
- 2014-12-03 US US15/101,392 patent/US9782418B2/en active Active
- 2014-12-03 EP EP14867137.3A patent/EP3077544B1/en active Active
-
2017
- 2017-07-18 US US15/653,480 patent/US10449202B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106029905A (zh) | 2016-10-12 |
| EP3077544B1 (en) | 2019-04-24 |
| US10449202B2 (en) | 2019-10-22 |
| US20160303140A1 (en) | 2016-10-20 |
| EP3077544A4 (en) | 2017-07-05 |
| WO2015084958A1 (en) | 2015-06-11 |
| US9782418B2 (en) | 2017-10-10 |
| US20180117061A1 (en) | 2018-05-03 |
| EP3077544A1 (en) | 2016-10-12 |
| CN106029905B (zh) | 2020-04-14 |
| PT3077544T (pt) | 2019-08-01 |
| AU2014360503A1 (en) | 2016-06-30 |
| DK3077544T3 (da) | 2019-07-08 |
| ES2732445T3 (es) | 2019-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245731A0 (en) | Combined treatment for cancer | |
| IL241232A0 (en) | Cancer treatment agents | |
| GB201322725D0 (en) | Cancer therapy | |
| EP2968348A4 (en) | COMPOUNDS FOR THE TREATMENT OF CANCER | |
| EP2968343A4 (en) | POLY THERAPY FOR TREATING CANCER | |
| HK1221424A1 (zh) | 治療癌症的藥物組合 | |
| HK1220900A1 (zh) | 癌症的治療 | |
| LT3077544T (lt) | Racionalia logika pagrįstas tikslinės vėžio terapijos modelis | |
| SG10201801965RA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| SG11201507847UA (en) | Cancer therapy | |
| HK1214128A1 (zh) | 癌症的治療 | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1204956A1 (en) | Treatment of cancer | |
| GB201310755D0 (en) | Therapy | |
| EP2961412A4 (en) | CANCER THERAPY | |
| GB201403083D0 (en) | Treatment of cancer | |
| EP2934500A4 (en) | COMBINATION THERAPY AGAINST CANCER | |
| HK1232118A1 (zh) | 癌症的治療 | |
| GB201308039D0 (en) | Photodynamic therapy | |
| GB201518731D0 (en) | Tumour Therapy | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| GB201217890D0 (en) | Treatment of cancer | |
| GB201317213D0 (en) | Cancer Therapy | |
| GB201308365D0 (en) | Tumour therapy |